Nefl Antibody

What is Nefl/NF-L and why is it significant in neuroscience research?

Nefl (Neurofilament Light Polypeptide) is a 68 kDa cytoskeletal intermediate filament protein specifically expressed in neurons. It associates with the 125 kDa NF-M and the 200 kDa NF-H to form neurofilaments, which constitute the main structural elements of axons and dendrites . These filaments are crucial for controlling the diameter of large axons and maintaining neuronal integrity.

Scientifically, Nefl is significant because:

• It serves as a specific neuronal marker for identifying neurons and their processes

• Mutations in the NEFL gene cause some forms of Charcot-Marie-Tooth disease

• Nefl accumulation occurs in various neurological diseases including ALS, giant axon neuropathy, and other neurodegenerative conditions

• Its detection in cerebrospinal fluid and blood is emerging as a biomarker for neuronal damage and disease progression

How do different clones of Nefl antibodies compare in experimental applications?

Different Nefl antibody clones show varying specificity and application performance based on their epitope recognition:

When selecting a clone, researchers should consider:

• The specific application requirements (western blot vs. immunohistochemistry)

• The species being studied

• The cellular compartment of interest (axonal vs. somatic localization)

• The need for co-labeling with other antibodies (considering host species)

What are the optimal protocols for Nefl antibody use in formalin-fixed paraffin-embedded (FFPE) tissue sections?

For successful Nefl detection in FFPE sections, the following methodological approach is recommended:

• Antigen Retrieval: Heat-induced epitope retrieval using basic antigen retrieval reagent is critical

  • Standard protocol: Incubate sections in retrieval buffer (pH 9.0) at 95°C for 20 minutes

  • Allow gradual cooling to room temperature for 20 minutes

• Antibody Concentration and Incubation:

  • Primary antibody dilutions typically range from 1:100 to 1:1000

  • For clone NR4: 1:200 dilution is recommended for routine use

  • For chicken polyclonal: 1:4,000 dilution has been validated

  • Incubation time: 1 hour at room temperature or overnight at 4°C

• Detection System:

  • Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody shows excellent results

  • DAB (brown) visualization with hematoxylin (blue) counterstaining

  • Specific staining should localize to neuronal cell bodies and processes

Key controls to include:

• Positive control: Hippocampus or cerebellum sections (known to express Nefl)

• Negative control: K562 human chronic myelogenous leukemia cell line (Nefl negative)

How should researchers address specificity concerns when working with Nefl antibodies?

Establishing antibody specificity is crucial for reliable results in Nefl research:

• Western Blot Validation:

  • Confirm single band detection at approximately 68 kDa

  • Use positive controls: SH-SY5Y human neuroblastoma cells, A172 human glioblastoma cells, or rat hypothalamus

  • Use negative controls: K562 cells or non-neuronal tissues

• Epitope Mapping:

  • Select antibodies with well-characterized epitope regions when possible

  • For C-terminal specific antibodies, consider potential post-translational modifications

  • Multiple antibodies targeting different epitopes can provide confirmatory evidence

• Cross-Reactivity Testing:

  • Validate antibody in knockout/knockdown models when available

  • Test reactivity across relevant species if performing comparative studies

  • Consider blocking peptide experiments to confirm specificity

• Multi-Method Confirmation:

  • Combine immunostaining with mRNA detection techniques

  • As seen in the search results, dual RNAscope® ISH-IHC can simultaneously detect NEFL mRNA (red) and protein (green/blue) in tissue sections

What strategies can resolve common issues with Nefl antibody performance in experimental applications?

How can Nefl antibodies be effectively utilized in studies of neurodegenerative diseases?

Nefl antibodies provide valuable tools for investigating neurodegenerative conditions:

• Visualization of Pathological Accumulations:

  • Neurofilament-rich accumulations are common in ALS, Charcot-Marie-Tooth disease, and giant axon neuropathy

  • Use immunohistochemistry with Nefl antibodies to identify these pathological features

  • Compare with healthy control tissues to characterize disease-specific patterns

• Mutation-Specific Studies:

  • In Charcot-Marie-Tooth disease caused by NEFL mutations , antibodies can help determine:

    • Whether mutant Nefl proteins form aggregates

    • The subcellular localization of mutant proteins

    • Co-localization with other neurofilament subunits

• Biomarker Development:

  • Combine Nefl antibodies in sandwich ELISA assays to quantify Nefl in:

    • Cerebrospinal fluid samples

    • Plasma or serum samples

    • Brain tissue extracts

  • Correlate levels with disease progression or treatment response

• Co-Localization Studies:

  • Pair Nefl antibodies with markers of neurodegeneration:

    • Phosphorylated tau (Alzheimer's disease)

    • α-synuclein (Parkinson's disease)

    • TDP-43 (ALS and frontotemporal dementia)

  • Use different host species antibodies for multi-label immunofluorescence

How are Nefl antibodies being integrated with emerging technologies in neuroscience research?

Recent methodological advances incorporating Nefl antibodies include:

• Integrated Multi-Omics Approaches:

  • Combined RNAscope® ISH-IHC techniques allow simultaneous detection of NEFL mRNA and protein in the same tissue section

  • This enables direct correlation between transcription and translation

  • Particularly valuable for studying regulatory mechanisms in disease states

• Advanced Microscopy Applications:

  • Super-resolution microscopy with Nefl antibodies reveals neurofilament organization at nanoscale resolution

  • Live cell imaging using fluorescently-tagged antibody fragments for dynamic studies

  • Expansion microscopy to physically enlarge samples for improved visualization of neurofilament networks

• Single-Cell Analysis:

  • Flow cytometry applications using Nefl antibodies can identify and isolate specific neuronal populations

  • Integration with single-cell transcriptomics for comprehensive profiling

  • Recommended dilutions for flow cytometry: 1:200-1:400

What are the critical considerations when selecting Nefl antibodies for cross-species neuroanatomical studies?

When conducting comparative studies across species, researchers should consider:

• Epitope Conservation Assessment:

  • Nefl protein is highly conserved but contains species-specific regions

  • Verify antibody epitope sequence conservation across target species

  • If epitope information is unavailable, test empirically in each species

• Cross-Reactivity Validation Table:

• Fixation and Processing Considerations:

  • Different species may require modified fixation protocols

  • Tissue processing can impact epitope accessibility differently across species

  • Antigen retrieval parameters may need species-specific optimization

• Anatomical Considerations:

  • Account for species differences in neuroanatomy when comparing results

  • Use established neuroanatomical landmarks appropriate for each species

  • Consider differences in neurofilament expression patterns during development

What are the recommended dilution ranges and optimization strategies for different Nefl antibody applications?

Optimization workflow:

• Start with manufacturer's recommended dilution

• Perform a dilution series (2-fold dilutions above and below recommended)

• Include positive and negative controls for each dilution

• Select optimal dilution based on signal-to-noise ratio

• Verify with biological replicates

How should researchers prepare and store Nefl antibodies to maintain optimal activity?

Proper handling of Nefl antibodies is crucial for experimental reproducibility:

• Initial Processing Upon Receipt:

  • Centrifuge vial briefly before opening (reduce protein aggregation at cap/walls)

  • Aliquot into smaller working volumes (10-30 μL/vial) to avoid freeze/thaw cycles

  • Use sterile conditions and low protein-binding tubes

• Storage Conditions:

  • Long-term storage: -20°C to -70°C for 6-12 months

  • Working aliquot: 4°C for up to 1 month

  • Avoid repeated freeze/thaw cycles (causes degradation and loss of activity)

  • Store in original buffer; do not dilute for storage

• Reconstitution of Lyophilized Antibodies:

  • Allow vial to reach room temperature before opening

  • Reconstitute with sterile water or buffer specified by manufacturer

  • Gently mix by inversion; avoid vigorous vortexing (prevents denaturation)

  • Allow complete dissolution before aliquoting (usually 5-10 minutes)

• Quality Control Practices:

  • Record date of receipt, lot number, and aliquoting date

  • Include expiration date on all aliquot tubes

  • Periodically validate activity against a reference sample

  • Monitor for signs of degradation (precipitates, color changes, decreased activity)

By implementing these storage and handling practices, researchers can maintain antibody activity and ensure experimental consistency.

How might Nefl antibody-based approaches contribute to precision medicine in neurological disorders?

Nefl antibody technologies are poised to advance personalized approaches to neurological disease:

• Diagnostic Applications:

  • Development of high-sensitivity immunoassays for earlier detection of neurodegeneration

  • Creation of antibody-based imaging agents for visualizing neurofilament pathology in vivo

  • Integration with other biomarkers to create neurological disease "fingerprints"

• Patient Stratification:

  • Using antibody-based detection of Nefl to identify disease subtypes

  • Correlating Nefl patterns with genetic information to guide personalized treatment

  • Predicting disease progression based on neurofilament dynamics

• Treatment Monitoring:

  • Developing antibody-based assays to track therapeutic efficacy

  • Creating point-of-care tests for regular monitoring of Nefl levels

  • Establishing Nefl-based companion diagnostics for emerging neurotherapeutics

• Therapeutic Applications:

  • Engineering antibodies to target pathological forms of Nefl

  • Developing antibody-drug conjugates for targeted delivery to affected neurons

  • Creating immunotherapeutic approaches to clear neurofilament aggregates